翰森制药引入透析领域创新药 深化肾科领域布局

格隆汇
Dec 28, 2025

格隆汇12月28日|翰森制药(3692.HK)宣布订立许可协议,获得创新药SHR6508于中国(不含港澳台)的独家开发、生产和商业化权益。据悉,SHR6508为钙敏感受体(CaSR)变构调节剂,目前处于Ⅲ期临床试验阶段,拟用于治疗需接受血液透析的慢性肾脏病(CKD)成年患者的继发性甲状旁腺功能亢进症。值得注意的是,翰森制药已于2023年上市一款肾科领域创新药圣罗莱®(培莫沙肽注射液),用于治疗肾...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10